Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | TPMT | P51580 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903560 | 0.87 | PKM (0.58) | KDM4EPOLBTPMTUSP2HSD17B10 | |
| Ammonia Solution, Strong SCHEMBL27859010 | 0.86 | PKM (0.57) | KDM4EPOLBTPMTUSP2HSD17B10 | |
| Syringate SCHEMBL30725929 | 0.86 | PKM (0.53) | KDM4EPOLBTPMTKMT2AMEN1 | |
| SCHEMBL12135968 | 0.82 | KDM4E (0.67) | KDM4EPOLBKMT2AMEN1USP2 | |
| Methyl Syringate SCHEMBL211747 | 0.82 | MEN1 (0.61) | KDM4EPOLBTPMTKMT2AMEN1 | |
| SCHEMBL27733832 | 0.77 | CA1 (0.52) | KDM4EPOLBKMT2AMEN1HSD17B10 | |
| SCHEMBL383326 | 0.76 | PKM (0.46) | KDM4EPOLBTPMTKMT2AMEN1 | |
| Gallic Acid Methyl Ester SCHEMBL4604139 | 0.76 | LMNA (0.57) | KDM4EPOLBTPMTHSD17B10PKM | |
| Gallic Acid Methyl Ester SCHEMBL5334274 | 0.76 | LMNA (0.57) | KDM4EPOLBTPMTHSD17B10PKM | |
| SCHEMBL24425750 | 0.76 | KMT2A (0.54) | KDM4EPOLBTPMTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776100-B1 | TREATMENT OF CANCER USING BENZOIC ACID DERIVATIVES | UNIV NEW YORK (US) | 2016-08-31 | — | — | EP | disclosed |
| US-9018259-B2 | Treatment of cancer using benzoic acid derivatives | NEW YORK UNIVERSITY (US) | 2015-04-28 | — | — | US | disclosed |
| US-20120329861-A1 | TREATMENT OF CANCER USING BENZOIC ACID DERIVATIVES | NEW YORK UNIVERSITY (US) | 2012-12-27 | — | — | US | disclosed |
| US-8198328-B2 | Treatment of cancer using benzoic acid derivatives | NEW YORK UNIVERSITY (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1776100-A4 | TREATMENT OF CANCER USING BENZOIC ACID DERIVATIVES | UNIV NEW YORK (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1776100-A2 | TREATMENT OF CANCER USING BENZOIC ACID DERIVATIVES | NEW YORK UNIVERSITY (US) | 2007-04-25 | — | — | EP | disclosed |
| US-20050209334-A1 | method of treating cancer using benzoic acid derivatives, alone or in combination with standard treatments such as chemotherapy and radiotherapy methods of screening for benzoic derivatives based on their ability to inhibit the enzyme tyrosinase or to bind to and activate PXR/SXR xenobiotic receptors. | NEW YORK UNIVERSITY (US) | 2005-09-22 | — | — | US | disclosed |
| WO-2005070024-A2 | TREATMENT OF CANCER USING BENZOIC ACID DERIVATIVES | NEW YORK UNIVERSITY (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209334-A1 | method of treating cancer using benzoic acid derivatives, alone or in combination with standard treatments such as chemotherapy and radiotherapy methods of screening for benzoic derivatives based on their ability to inhibit the enzyme tyrosinase or to bind to and activate PXR/SXR xenobiotic receptors. | AHR, TYR, CYP4X1 | KDM4E 2567/4885POLB 1324/4885TPMT 433/4885 |
| US-20120329861-A1 | TREATMENT OF CANCER USING BENZOIC ACID DERIVATIVES | AHR, TYR, CYP4X1 | KDM4E 2533/4885POLB 1222/4885TPMT 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.